This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2003 Jun 15;21(12):2227-9.

doi: 10.1200/JCO.2003.04.001. Epub 2003 May 14.

Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

David H Johnson, Carlos L Arteaga

PMID: 12748243
DOI: 10.1200/JCO.2003.04.001

Editorial

Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

David H Johnson et al. J Clin Oncol. 2003.

. 2003 Jun 15;21(12):2227-9.

doi: 10.1200/JCO.2003.04.001. Epub 2003 May 14.

Authors

David H Johnson, Carlos L Arteaga

PMID: 12748243
DOI: 10.1200/JCO.2003.04.001

No abstract available

PubMed Disclaimer

Comment on

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Fukuoka M, et al. J Clin Oncol. 2003 Jun 15;21(12):2237-46. doi: 10.1200/JCO.2003.10.038. Epub 2003 May 14. J Clin Oncol. 2003. PMID: 12748244 Clinical Trial.

Similar articles

Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP, Ramalingam S. Belani CP, et al. Clin Lung Cancer. 2005 Jan;6(4):203-4. Clin Lung Cancer. 2005. PMID: 15694010 No abstract available.
Gefitinib plus docetaxel in non-small-cell lung cancer.
Singh N, Aggarwal AN. Singh N, et al. Lancet. 2009 Feb 14;373(9663):541-2; author reply 542. doi: 10.1016/S0140-6736(09)60194-X. Lancet. 2009. PMID: 19217980 No abstract available.
Gefitinib for refractory advanced non-small-cell lung cancer.
Moriguchi H, Kim TY, Sato C. Moriguchi H, et al. Lancet. 2006 Jan 28;367(9507):299-300. doi: 10.1016/S0140-6736(06)68063-X. Lancet. 2006. PMID: 16443032 No abstract available.
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Kelly K, Averbuch S. Kelly K, et al. Semin Oncol. 2004 Feb;31(1 Suppl 1):93-9. doi: 10.1053/j.seminoncol.2003.12.020. Semin Oncol. 2004. PMID: 14981586 Review.
[Iressa (gefitinib)].
Kudoh S, Yoshimura A, Gemma A. Kudoh S, et al. Gan To Kagaku Ryoho. 2003 Aug;30(8):1079-84. Gan To Kagaku Ryoho. 2003. PMID: 12938261 Review. Japanese.

See all similar articles

Cited by

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.
Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, Giannopoulou I. Magkou C, et al. Breast Cancer Res. 2008;10(3):R49. doi: 10.1186/bcr2103. Epub 2008 Jun 3. Breast Cancer Res. 2008. PMID: 18522728 Free PMC article.
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Massarelli E, et al. Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29. Ann Oncol. 2015. PMID: 26025965 Free PMC article. Clinical Trial.
HER2 expression as a potential marker for response to therapy targeted to the EGFR.
Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE. Emlet DR, et al. Br J Cancer. 2006 Apr 24;94(8):1144-53. doi: 10.1038/sj.bjc.6603078. Br J Cancer. 2006. PMID: 16622439 Free PMC article.
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).
Stebbing J, Harrison M, Glynne-Jones R, Bridgewater J, Propper D. Stebbing J, et al. Br J Cancer. 2008 Feb 26;98(4):716-9. doi: 10.1038/sj.bjc.6604232. Epub 2008 Feb 5. Br J Cancer. 2008. PMID: 18253119 Free PMC article. Clinical Trial.
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E, Grimaldi GC, Roncalli M, Santoro A. Parra HS, et al. Br J Cancer. 2004 Jul 19;91(2):208-12. doi: 10.1038/sj.bjc.6601923. Br J Cancer. 2004. PMID: 15187994 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information